No one should have expected anything but a CRL. I'm adding aftermarket.
the story here is far from over.
D
Is there anyone who actually believes they will receive a positive decision on June 27? I know they received feedback that their "data package may be insufficient." I have been investing in small biotechs for years but cannot recall if there have been any recent examples of successful application after such a correspondence (unless, of course, the application was supplemented). I am trying to determine whether to hold my recently acquired position or peel a lot of it back.
S
Again, a study the FDA was visible to the design was not good enough for the FDA when it came to approval time. This keeps happening over and over. Companies being set up like bowling pins by the FDA. Thanks FDA.
P
Bought my first SPRO position. Technically, it looks like the risk reward is favorable and their cash is adequate enough to buy them some time.
A
I picked some more up
Once everything shakes out this name is well over a buck.
v
25 days to PDUFA. One month ago Spero announced suspension of commercialization activities for tebipenem HBr, due to feedback from an FDA Late Cycle Meeting. Any thoughts what may happen on 27 June?
L
It's unbelievable that hardly anyone recognizes the potential of this stock at $1. Hey, wake up people, this is 1,000,000 times better odds than buying a lottery ticket. Putting up a hundred bucks for a hundred shares is a no-brainer. It always makes me laugh out loud when people turn away from a stock because it's too cheap to be worthwhile. Wake up, people. Wake up!
A
this mutt has been forgotten
i picked up a few shares
R
Read the 8K. Cash is dwidling and company is paying back to investors group $54 million
F
Gonna pop soon.....
D
I wonder what the future of tebipenem is now? I can't really decipher from the info they provide. That was the reason i bought this stock in the first place. I think a big pharma like PFE will buy them out but don't see a big premium buyout offer making sense at this point.
v
Where is the bottom in this hihghly manipulated market? A buck for spro? Madness
J
why is this moving up afterhours
D
Easy buy right here under 2. Do the basic math of shares, cash, and debt. Then look at drugs in the pipeline. 4 dollars minimum.
D
$3 by Tuesday. Above average volume with steady gains at the end of last week. Cash rich, low float, buyout possibility.
s
I listened to presentation after new restructuring. I does not look like SPRO is worth 1/3 of cash. Very bullish BTW
D
They have cash and pipelines to last another 1-2 years: "In connection with this development, Spero announced that it is undertaking a reduction in its workforce by approximately 75% and a restructuring of its operations to reduce operating costs and reallocate resources towards the clinical development programs of SPR720 and SPR206, while continuing engagement with the FDA on the appropriate path forward for tebipenem HBr. Based on the anticipated cost-savings of this restructuring and other assumptions, Spero anticipates it will be able to fund its planned operating expenses and capital expenditure requirements pursuant to the priorities of its strategic refocusing through late 2023".....
T
Red to green soon ….. still holding this one ….. midday spike coming ….. $3 written all over it …..
T
SPRO "Please buy our company." Buyer "How much?" SPRO "No cost to you. We'll actually pay you over $100 million in cash for the transaction." Buyer "Is this a scam?" SPRO "No, it's just the irrational nature of the stock market. To note, this offer may not be around for long."
T
They have $146 million cash on hand and current value in the premarket is $46 million?. Wow, this seems way overcooked on the downside...
the story here is far from over.
Once everything shakes out this name is well over a buck.
i picked up a few shares
"In connection with this development, Spero announced that it is undertaking a reduction in its workforce by approximately 75% and a restructuring of its operations to reduce operating costs and reallocate resources towards the clinical development programs of SPR720 and SPR206, while continuing engagement with the FDA on the appropriate path forward for tebipenem HBr. Based on the anticipated cost-savings of this restructuring and other assumptions, Spero anticipates it will be able to fund its planned operating expenses and capital expenditure requirements pursuant to the priorities of its strategic refocusing through late 2023".....
Buyer "How much?"
SPRO "No cost to you. We'll actually pay you over $100 million in cash for the transaction."
Buyer "Is this a scam?"
SPRO "No, it's just the irrational nature of the stock market. To note, this offer may not be around for long."